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Abstract: Thymoquinone (TQ) is the main active ingredient of Nigella sativa essential oil,
with remarkable anti-neoplastic activities with anti-invasive and anti-migratory abilities on a
variety of cancer cell lines. However, its poor water solubility, high instability in aqueous solution
and pharmacokinetic drawbacks limits its use in therapy. Soluplus® and Solutol® HS15 were
employed as amphiphilic polymers for developing polymeric micelles (SSM). Chemical and physical
characterization studies of micelles are reported, in terms of size, homogeneity, zeta potential,
critical micelle concentration (CMC), cloud point, encapsulation efficiency (EE%), load capacity (DL),
in vitro release, and stability. This study reports for the first time the anti-migratory activity of TQ
and TQ loaded in SSM (TQ-SSM) in the SH-SY5Y human neuroblastoma cell line. The inhibitory
effect was assessed by the wound-healing assay and compared with that of the unformulated TQ.
The optimal TQ-SSM were provided with small size (56.71 ± 1.41 nm) and spherical shape at ratio of
1:4 (Soluplus:Solutol HS15), thus increasing the solubility of about 10-fold in water. The entrapment
efficiency and drug loading were 92.4 ± 1.6% and 4.68 ± 0.12, respectively, and the colloidal dispersion
are stable during storage for a period of 40 days. The TQ-SSM were also lyophilized to obtain a more
workable product and with increased stability. In vitro release study indicated a prolonged release of
TQ. In conclusion, the formulation of TQ into SSM allows a bio-enhancement of TQ anti-migration
activity, suggesting that TQ-SSM is a better candidate than unformulated TQ to inhibit human
SH-SY5Y neuroblastoma cell migration.
Keywords: thymoquinone; polymeric micelles; Soluplus®; Solutol® HS15; solubility; stability;
neuroblastoma; cell migration; wound-healing assay
1. Introduction
Neuroblastoma (NB) is by far the most common extracranial solid tumor diagnosed in infancy,
with an average age of 1–2 years at the diagnosis. It is a neuroendocrine tumor that originates from the
developing sympathetic nervous system and with a highly variable clinical picture, depending on
the stage and location of the tumor. It accounts for 7% of all childhood cancers with nearly 500 new
cases each year and 15% of all cancer deaths in the pediatric population [1]. Generally, the risk of many
Molecules 2020, 25, 4707; doi:10.3390/molecules25204707 www.mdpi.com/journal/molecules
Molecules 2020, 25, 4707 2 of 17
cancers in adults can be reduced with some lifestyle changes (such as an adequate dietary intake and
exercise or stopping smoking and alcohol abuse), but currently, there is no way to prevent most cancers
in children. At present, there are no causes of neuroblastomas linked to lifestyle or the environment,
while the only known risk factors (age and heredity) cannot be changed. Moreover, despite the clinical
progress with multimodal intensive care, including surgical resection, chemotherapy, immunotherapy,
radiotherapy, myeloablative treatment, or retinoid therapy, these treatment options are often toxic and
not always effective [2,3]. As a matter of fact, more than half of children with high-risk aggressive NB
are still suffering from refractory or relapsing diseases developing widespread metastasis, especially in
liver, non-contiguous lymph nodes, bone marrow, and other organs [4]. Mostly of patients with
refractory or relapsed disease the lack of curative treatment solutions makes the overall mean survival
extremely low [5]. Therefore, new innovative approaches are urgently needed to avoid refractory or
relapsing disease and to increase the rate of survival. Among various therapeutic options, targeting
tumor cell invasion and migration is a possible strategy against tumor progression [6].
Currently, there is a general tendency to select new anticancer agents from natural products
because they are generally related to relatively less toxicity and minimal side effects. Over the years,
the study of traditional or popular medicine along with modern medicine has allowed researchers to
identify active compounds for the development of functional foods for strategic dietary interventions
aimed at preventing the progression of chronic diseases, such as cancer metastases [7,8].
Rich in history and tradition, Nigella sativa L. (black cumin), belonging to the Ranunculaceae
family, is a plant today known as “miraculous herb” for its wide range of pharmacological potential [9].
The folkloristic use of black cumin seeds and their oil as food or herbal drug preparation in medical
practices against various human diseases was particularly widespread in South and Southeast Asia,
Africa, Arabia, and in the Mediterranean regions. Most of the beneficial pro-health properties of
this plant are attributed to thymoquinone (2-isopropyl-5-methyl-benzo-1,4-quinone, TQ) (Figure 1),
the most important active ingredient of black cumin essential oil [9–11].
Figure 1. Structure of thymoquinone.
TQ has versatile bioactive properties, with antioxidant, anti-inflammatory, immunomodulatory,
antihistaminic, analgesic, antidiabetic, antimicrobial, and antiviral effects. The compound also has
beneficial effects in cardiovascular, reproductive, diabetes, respiratory, and neurological disorders,
as well as in the management of bone complications and fibrosis. Moreover, TQ has shown remarkable
anti-neoplastic activities with anti-invasive and anti-migratory abilities on a variety of cancer cells,
including human glioblastoma and murine neuroblastoma cells [12,13], colon cancer cells [14], breast
cancer cells [15], human non-small cell lung cancer cells [16], vascular smooth muscle cells [17] and
cervical cancer cells [18]. Furthermore, many studies agree that TQ has no significant adverse effects
and no serious toxicity [19,20]. Despite its great nutraceutical potential, TQ is poorly soluble in
water (550 µg/mL), unstable in aqueous solutions, particularly at an alkaline pH, and it has severe
light sensitivity [21]. TQ has shown high instability, rapid elimination and a great ability to bind to
plasma membranes limiting the effectiveness of its beneficial effect [21] and, consequently, its clinical
use [22]. Then, the aqueous solutions are inappropriate as pharmaceutical vehicles for TQ preparations.
Therefore, the focus on nanotechnology to improve bioavailability and drug delivery is of growing
importance. The use of new alternative therapeutic delivery systems, such as nanocarriers, can improve
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efficacy and reduce systemic toxicity during the treatment of malignant tumors compared to the use of
“free” drugs [23].
To overcome the drawbacks of TQ, several strategies have been employed including polymeric
nanoparticles, lipid carriers, micro and nanoemulsions, Self-Emulsifying Drug Delivery Systems,
cyclodextrin complexes, and liposomes. These nanocarriers ameliorate the bioavailability and
the anticancer and anti-inflammatory activities of TQ when compared with free substance.
The encapsulation in nanoparticles improves the delivery and limits undesirable cytotoxicity [24–27].
Among the varieties of nanoformulations available to improve biopharmaceutics properties of
drugs, polymeric micelles (PM) are of great interest for pharmacological application [28]. Food and
Drug Administration (FDA) approved Genexol® PM, a micellar formulation of paclitaxel for the
treatment of breast, ovarian and lung cancer [29].
Polymeric micelles are core/shell structures with nanoscopic dimensions, consisting of amphiphilic
blocks copolymers formed by a hydrophilic (e.g., polyethylene glycol (PEG), polyvinylpyrrolidone
(PVP)) and a lipophilic portion (e.g., polyesters, polyanhydrides, and polyaminoacids). They are
particularly well suited for drug delivery purposes due to their inherent and modifiable properties.
The advantages include solubilization of poorly soluble molecules, sustained release and size
advantages, and protection of encapsulated substances from degradation and metabolism [30].
Such nanoparticulate systems are made of synthetic or natural polymers which can be modified to
modulate the drug release kinetics. PM result safe and usable for parenteral administration, permitting
a rise within the dose of potent yet toxic and poorly water-soluble compounds. Polymeric micelles
may circulate for extended periods in blood and gradually release drug. Based on their constituents,
they can inhibit P-glycoprotein at drug-resistant tumors, gastrointestinal tract, and blood/brain barrier,
perhaps providing some way to beat drug resistance in cancer and increase drug absorption from the
gut and drug absorption into the brain [31]. Many of these properties are connected to the hydrophilic
portion of the PM, in particular the PEG moiety. The low cost, the limited toxicity and the high degree
of hydration that stabilizes in an aqueous medium the nanostructured systems explain the wide use of
this polymer [32,33].
Among pegylated copolymers, Soluplus® is a tri-block copolymer consisting of
polyvinylcaprolactam-polyvinylacetate-polyethylene glycol (Figure 2). It has a low critical micelle
concentration (CMC) and its micelles are highly stable after dilution [34,35]. It is an innovative excipient
that gives new levels of solubility and bioavailability of poorly water-soluble drugs and natural
compounds both for oral and parenteral administration [35–45]. Solutol® HS15 (polyoxyethylene
esters of 12-hydroxystearic acid, Figure 2) is a known non-ionic surfactant with high solubility and
stability and low toxicity in vivo. It consists of a lipophilic and a hydrophilic portion, which comprise
mono- and di-esters polyglycols of 12-hydroxystearic acid and about 30% of free polyethylene glycol,
respectively. It is a multi-drug resistance modifying agent both in vitro and in vivo [46,47]. It alters the
binding to plasma proteins, improving the adsorption behavior and inducing marked effects on the
pharmacokinetics of numerous drugs [48]. Like Soluplus®, it is a solubilizer particularly suitable for
parenteral and oral dosage forms [49–52].
Given the considerable variety of nanoformulations, described in the literature, available
to improve biopharmaceutical properties of drugs, in this study for the first time the mixed
Soluplus®–Solutol® HS15 micelles (SSM) were applied to TQ delivery with the aim to increase
its the aqueous solubility and bioactivity. The two polymers were also selected for their low toxicity
and known use for parenteral administration.
Moreover, for the first time the anti-migratory capacity of TQ formulated in SSM (TQ-SSM)
was investigated on the SH-SY5Y human neuroblastoma cell line. In a previous study, the authors
have shown that the nanoformulation of Posidonia oceanica extract allows improvement of the extract
inhibitory activity against cell migration [39], due to effect on the solubility of the extract and the
modulation of its release.
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Figure 2. Chemical structures of Soluplus® and Solutol® HS15.
Chemical and physical characterization studies, in terms of size, homogeneity, zeta potential,
CMC, cloud point, encapsulation efficiency, load capacity, in vitro release, and storage stability,
were performed on empty SSM and TQ-SSM. In addition, the stability of the formulations was
investigated in vitro in blood conditions and the lyophilization was evaluated as a useful process to
obtain a solid product. Finally, the inhibitory effect of TQ-SSM on SH-SY5Y cell migration was assessed
by the wound-healing assay and compared with that of the unformulated TQ.
2. Results and Discussion
2.1. Preparation and Characterization of TQ-SSM
Polymeric micelles were developed to improve the aqueous solubility of TQ and to test the
influence of the carrier on the inhibitory potential on cancer cell migration, providing a sustained and
prolonged release. Different Soluplus® and Solutol® HS15 gravimetric ratios (1:1, 1:4, 2:1, 2:3, 4:3,
4:5) were considered to obtain a formulation with high encapsulation efficiency and with appropriate
technological parameters for parenteral administration and stability features. Several amount of
TQ, from 2 mg/mL to 6 mg/mL, were also considered. Nevertheless, tested formulations displayed
adequate sizes between 50 and 60 nm with narrow distribution (PDI < 0.2) but many of them did not
have good physical stability or high encapsulation efficiency.
Finally, the optimized formulation consisted of Soluplus:Solutol 1:4 gravimetric ratio (SSM) and it
is able to load 5 mg/mL of TQ, with an EE% of 92.4 ± 1.6% and DL% of 4.68 ± 0.12. Moreover, the TQ
presence did not affect the physical and chemical characteristics and the stability of empty micelles
(Table 1). The TQ solubility is increased about 10-fold in water.
Table 1. Physical and chemical properties of empty SSM and TQ-SSM. All values are expressed as
means ± standard deviation.
Particle Size (nm) Polydispersity Index (PDI) Zeta Potential (mV) EE (%) DL (%)
SSM 49.25 ± 1.92 0.183 ± 0.028 −5.46 ± 0.38 - -
TQ-SSM 56.71 ± 1.41 0.177 ± 0.007 −8.53 ± 0.27 92.4 ± 1.6 4.68 ± 0.12
TQ-SSML 52.12 ± 1.18 0.183 ± 0.00 −7.89 ± 0.32 89.8 ± 0.2 4.11 ± 0.17
The freeze-drying process in the absence of cryoprotectant was also considered to increase the
stability of the formulation (TQ-SSML) over a prolonged period and to obtain a more workable
product. The freeze-dried process did not modify the size and homogeneity of the samples when
the freeze-dried product was re-dispersed in water: the physical and chemical parameters before
and after the process are substantially comparable (Table 1). The formulation is easily re-dispersible,
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without leaving undissolved solid. This is due to the presence of the two polymers that protect TQ and
quickly rehydrate.
2.2. Self-Aggregation of Polymeric Micelles and Cloud Point
The CMC is an essential parameter influencing the stability of the micelles in vitro and
in vivo [35,36,38]. Soluplus® is a hydrophilic graft copolymer, which can easily form colloidal
micelles with very good solubilization ability and stability, due to its low value of CMC
(0.76 × 10−3%, 0.0003 mM) [53,54]. Solutol® HS15 has a CMC of 0.005–0.02% (0.06 mM in distilled
water) [55]. Thanks to its unique solubilization characteristics and safety profiles, this excipient has
been used in parenteral, oral, ophthalmic, macromolecule, and protein formulations. The CMC of
each copolymer and the molar fraction of the polymers in SSM were considered to evaluate the
self-aggregation capacity of mixed micelles by calculating the theoretical CMC [40,56]. The CMC value
resulted 1.82 × 10−3 mM. The low CMC value ensures the TQ-SSM high stability in the blood stream
upon extreme dilution.
The cloud point is the temperature at which a non-ionic surfactant solution becomes cloudy
due to the two-step separation when the system is heated. The phenomenon is explained by the
dehydration of the surfactant with increasing temperature and by a decrease in the solubility of the
surfactant [57]. The cloud point helps to select the storage conditions and to predict the stability
of the formulation after administration. In this work the cloud point of TQ-SSM was found to be
30.7 ± 0.4 ◦C (mean ± SD, n = 3) and the cloud point of empty SSM is 29.5 ± 0.5 ◦C (Mean ± SD, n = 3).
Despite the not very high value, the system maintained the same size and homogeneity as resulted
by DLS analyses. As previously reported [40,56], the cloud point of a system is influenced by the
inter-micellar interactions of the polymers, and the physicochemical characteristic of the mixed micelles
may substantially differ from that of single micelles. Soluplus has a cloud point of 40.7 ± 0.8 ◦C
(Mean ± SD, n = 3) [40], while Solutol® HS15 of 70.0 ± 0.7 ◦C (Mean ± SD, n = 3) [58].
2.3. In Vitro Release
The dialysis bag method was applied to study the release of TQ from micelles. PBS (pH 7.4) was
used as a release medium, the test was carried out in the sink conditions. Maintaining a sink condition
means keeping the drug concentration in a release medium low enough not to affect the concentration
gradient for drug release. For this aim, at predetermined time intervals, 1 mL of release medium
was withdrawn for HPLC analyses and replaced with the same volume of fresh release medium.
As demonstrated by Figure 3, the immediate release of the drug was found for free TQ, while in the
case of TQ-SSM the release of TQ takes place gradually until a maximum percentage of 51.50 ± 2.44%
in 24 h. The almost linear and gradual trend of the release indicated that the SSM systems can release
TQ for prolonged periods and in greater quantities compared to the saturated aqueous solution.
The results also revealed that TQ released from the polymeric micelle follows a slow and constant
release rate compared to free TQ and after 6 h the percentage of drug release was in a plateau.
However, SSM avoid rapid TQ release in the early hours unlike free TQ and this this slow release could
prevent the degradation of TQ during the delivery and blood circulation.
2.4. Stability Storage
Stability studies on nanodelivery system represent an important issue for the applicability of
the formulation in daily practice and thinking about an industrial production. The stability of
TQ-SSM as dispersion was monitored during 40 days at 4 ◦C (Figure 4), because the stability at
+25 ◦C was limited to 2 weeks, with a worsening of chemical stability. The physical parameters
remained practically unchanged during the storage period. The size ranges from 56.71 ± 1.41
to 55.39 ± 1.13, PDI from 0.180 ± 0.003 to 0.176 ± 0.006 and zeta potential from −8.53 ± 0.27 to
−7.81 ± 0.32. Also, regarding chemical stability, the EE% and DL% values remain the same even after
Molecules 2020, 25, 4707 6 of 17
40 days, 90.23 ± 0.33 and 4.02 ± 0.14, respectively. No turbidity and layer separations were observed
in the colloidal dispersion during the 40 days.
Figure 3. In vitro release profiles in PBS (pH 7.4) of TQ from aqueous saturated solution (TQ) and from
micelles TQ-SSM.
Figure 4. Particle size and polydispersity index (PDI) of TQ-SSM as dispersion after 40 days’ storage at
4 ◦C. Data displayed as mean ± SD (n = 3).
Furthermore, the stability study was performed on freeze-dried product (TQ-SSML) for 1 month
at +25 ◦C. The solid product remains stable with sizes of 58.95 ± 2.31 and PDI of 0.205 ± 0.011.
After the hydration, the formulation is easily re-dispersible, without leaving undissolved solid.
Then, two possible ways to improve the stability of the micellar formulation is keeping the product in
the fridge or eliminating water from the formulation.
2.5. Stability in the Presence of Human Serum Albumin (HSA)
TQ-SSM showed a slight increase in terms of PDI and particle size when incubated with PBS in
the presence of HSA compared to the condition of PBS only (Figure 5). This was probably due to the
coexistence of albumin and micelles. However, it is evident that the formulation does not undergo
drastic changes suggesting that the micelles are able to maintain their structure in physiological pH
conditions and also in the presence of plasma proteins, as a result of the shielding effect of the PEG
moiety. The same behavior was observed with empty micelles SSM: the average diameter ranges from
56.7 ± 1.3 nm to 71.95 ± 2.2 nm (Mean ± SD, n = 3) after 1 h when incubated with PBS and HSA.
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Figure 5. Stability of TQ-SSM in PBS and PBS + HSA for 1 h.
2.6. TQ Effect on SH-SY5Y Cell Migration
The TQ effect on SH-SY5Y cell viability was determined by MTT assay. As illustrated in Figure 6A,
TQ showed no signs of toxicity in terms of cell viability at concentrations from 1.5 to 10 µM while
maintaining the cell viability level unchanged from that of untreated control cells. Only about 20 ± 4%
reduction in cell viability was observed in cells treated with 15 µM TQ.
Figure 6. Effect of TQ on SH-SY5Y cell viability and migration. (A) MTT assay on cells treated with various
TQ concentrations for 24 h under starvation condition. Untreated cells were used as control. Data are
reported as percentage values compared to untreated control cells and expressed as the mean ± standard
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deviation of at least three independent experiments. (B) Time course analysis of the scratch closure
of SH-SY5Y cells treated following the same experimental condition above described. Wound width
values were measured considering the horizontal distance between the initial scratch and the scratch
after migration at different time points and were reported as a percentage ratio with respect to the
0 h time point. Data are expressed as the mean ± standard deviation of at least three independent
experiments. Error bars represent standard deviation. ** p-value < 0.01, *** p-value < 0.001 vs. untreated
control cells.
In the literature it is widely reported that TQ can suppress the migration of cancerous cells [12–18],
including mouse neuroblastoma cancer cells [13]. For the first time this work explored the effect of TQ
also on human SH-SY5Y neuroblastoma cell migration.
First, the effect of TQ on SH-SY5Y cell migration was observed in vitro using wound-healing
assays. Cells were treated under starvation conditions with completely non-toxic TQ doses (1.5 to
10 µM) to rule out any possible cytotoxicity interference on cell migration events. The wound was
performed on cell monolayers and cell migration was monitored at time intervals. Finally, the distance
traveled by the SH-SY5Y cells in the scratch area has been quantitatively defined.
Specifically, TQ exhibited a dose-dependent ability to inhibit cell migration. As depicted in
Figure 6B, as early as 5 h after the initial scratch, the wound width was approximately 80 ± 4% and
70 ± 3% of the initial width in cells treated with 10 and 6 µM of TQ, respectively, while untreated
control cells migrated up to 50 ± 2% of wound width. Thus, TQ showed a slightly lower, but still
effective inhibitory activity on cell migration at 3 and 1.5 µM concentrations (60 ± 6% and 60 ± 4%
of wound width, respectively). The TQ inhibition activity remained reasonably high in subsequent
time points. At 7 h from the initial scratch, cells treated with 10 and 6 µM of TQ migrated rather
slowly, so the wound width was 73 ± 6% and 60 ± 7%, respectively (about 10% less width than 5 h),
while untreated control cells migrated faster to a wound width of 30 ± 6% (20% less width than 5 h).
Cells treated with 3 and 1.5 µM of TQ had an intermediate behavior, so at 7 h the wound width was
respectively about 48 ± 2% and 42 ± 4% (approximately 15% less width than 5 h). After 24 h only cells
treated with 1.5 µM TQ reached wound closure exactly as untreated control cells, while cells treated
with the highest TQ doses (10, 6 and 3 µM) maintained a wound opening of 33 ± 3%, 24 ± 7%, 11 ± 1%,
respectively. The doses of TQ, here considered effective, agree with the literature [59].
2.7. The Bio-Enhancement of TQ Activity Once Loaded into SSM Polymeric Micelles
Since mixed Soluplus®-Solutol® HS15 micelles (SSM) are a standard and conventional
nanoformulations widely used for application in biopharmaceutical studies [49,60] in this work
the ability of SSM to improve the inhibitory role of TQ on human SH-SY5Y neuroblastoma cell
migration was explored.
Hence, to investigate a potential bio-enhancement of TQ activity, TQ (5 mg/mL) was loaded into
SSM polymeric micelles. Initially, to select the TQ-SSM doses at which the final biological effect could
undoubtedly be attributed to TQ excluding any interference from SSM, the effect of empty SSM was
examined on cell viability and migration. Then, SH-SY5Y cells were treated with empty SSM at 1:3000,
1:5000 and 1:10,000 dilutions, corresponding to the final loaded TQ concentrations of 10, 6 and 3 µM,
i.e., the higher doses proven effective in inhibiting cell migration.
Although empty SSM did not affect cell viability, which remained comparable to that of untreated
control cells (Figure 7A), a noticeable impact of SSM 1:3000 on cell migration was nevertheless observed.
As illustrated in Figure 7B, there was a slowdown in the migration of SSM 1:3000-treated cells as early
as 5 h (77 ± 2% of wound width) which persisted even after 7 h (65 ± 2% of wound width) preventing
the wound from closing after 24 h (26 ± 5% of wound width). Therefore, over time the wound width
was constantly wider by about 30% compared to that of untreated control cells. At the higher dilutions
1:5000 and 1:10,000, the impact of empty SSM on cell migration was moderately reduced. In fact,
in SSM 1:5000 or SSM 1:10,000 treated cells, the wound was only 5–10% wider over time (60 ± 2% and
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56 ± 4% of wound width, respectively, at 5 h; 51 ± 8% and 38 ± 2% of wound width, respectively, at 7 h)
compared to untreated control cells. However, this mild inhibiting effect was no longer evident at 24 h
when wound closure was complete as in untreated control cells.
Figure 7. Effect of empty SSM on SH-SY5Y cell viability and migration. (A) MTT assay on cells treated
with empty SSM at appropriate dilutions for 24 h under starvation condition. Untreated cells were used
as control. Data are reported as percentage values compared to untreated control cells and expressed as
the mean ± standard deviation of at least three independent experiments. (B) Time course analysis of
the scratch closure of SH-SY5Y cells treated following the same experimental condition above described.
Wound width values were reported as a percentage ratio with respect to the 0 h time point. Data are
expressed as the mean ± standard deviation of at least three independent experiments. Error bars
represent standard deviation. ** p-value < 0.01, *** p-value < 0.001 vs. untreated control cells.
Knowing the action of SSM on cell viability and migration, we decided to test TQ-SSM at dilutions
1:5000 and 1:10,000, at which empty SSM showed no effects on cell viability and migration while
the corresponding concentrations of unformulated 6 and 3 µM TQ showed efficacy in inhibiting
cell migration.
Figure 8A shows representative images of the wound-healing assay on cells treated with TQ-SSM.
As illustrated in Figure 8B, cells treated with TQ-SSM 1:5000 migrated more slowly to a wound width of
79 ± 4% at 5 h, 70 ± 4% at 7 h and 32 ± 2% at 24 h compared to cells treated with unformulated 6 µM TQ.
These data suggest that TQ-SSM 1:5000 allowed to improve the TQ inhibitory activity by approximately
10%. A very similar trend occurred for cells treated with TQ-SSM 1:10,000 (Figure 8C). At 5 h the
wound width was 70 ± 2%, approximately 10% wider than that of cells treated with unformulated
3 µM TQ. Even at 7 h TQ-SSM 1:10,000 improved the inhibition of cell migration by about 15% (65 ± 3%
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of the wound width) compared to cells treated with unformulated 3 µM TQ and about 20% at 24 h
(30 ± 4% of the wound width).
Figure 8. TQ-SSM effect on SH-SY5Y cell migration. (A) Representative image of SH-SY5Y cells,
untreated or treated with empty SSM, TQ, or TQ-SSM for 24 h under starvation conditions. Scratch
closure was monitored over time in cells. The dashed lines mark the edges of the wound area. (B) Time
course analysis of the scratch closure of SH-SY5Y cells treated with TQ-SSM 1:5000, TQ 6 µM or
SSM 1:5000. (C) Time course analysis of the scratch closure of SH-SY5Y cells treated with TQ-SSM
1:10,000, TQ 3 µM or SSM 1:10,000. Wound width values were reported as a percentage ratio with
respect to the 0 h time point. Data are expressed as the mean ± standard deviation of at least three
independent experiments. Error bars represent standard deviation. ** p-value < 0.01, *** p-value < 0.001
vs. untreated control cells; ◦◦ p-value < 0.01, ◦◦◦ p-value < 0.001 vs. TQ-treated cells.
Overall, these data highlight that the loading of TQ into SSM polymeric micelles allows a
bio-enhancement of TQ anti-migration activity, suggesting that TQ-SSM is a better candidate than
unformulated TQ to inhibit human SH-SY5Y neuroblastoma cell migration. Probably, the carrier
influences not only the solubility, but also the permeability of the TQ, providing an increase of
its activity.
To date, cancer nanotechnology as a means of providing anticancer drugs is a promising strategy
for cancer treatment. Our interesting results on the bio-enhancement of TQ activity once loaded into
SSM suggest that the application of nanotechnology could represent a successful strategy for future
clinical translation. Interestingly, the ability of nanotechnology to improve TQ bioactivity could be
exploited as a strategic tool for the known therapeutic uses of TQ.
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3. Materials and Methods
3.1. Chemicals and Reagents
BASF (Badische Anilin- und Soda Fabrik, Ludwigshafen, Germany) with the support of BASF Italia
and BTC Chemical Distribution Unit (Cesano Maderno, Monza, and Brianza, Italy) kindly provided
Soluplus® and Solutol® HS15. Distilled water was obtained from a Simplicity® UV Water Purification
System, Merck Millipore (Merck KGaA, Darmstadt, Germany). Thymoquinone, Phosphate buffered
saline BioPerformance Certified pH 7.4 (PBS), Tween® 80, lecithin (≥99%, TLC) lyophilized powder,
cholesterol BioReagent (≥99), Methanol HPLC grade, Acetonitrile HPLC grade, Dimethyl sulfoxide
(DMSO) HPLC grade, Formic acid analytical grade, 1,7-octadiene (98%), Dichloromethane (CH2Cl2)
were purchased from Sigma–Aldrich (Milan, Italy). Sigma–Aldrich Merck (Milan, Italy) also supplied
Dulbecco’s modified Eagle’s medium (DMEM), Ham’s F-12 nutrient mixture, fetal bovine serum (FBS),
L-glutamine, penicillin and streptomycin, 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl formazan (MTT)
and other chemicals. Disposable plastics were obtained from Sarstedt (Nümbrecht, Germany).
3.2. Preparation of Thymoquinone-Loaded Mixed Micelles (TQ-SSM)
TQ-SSM were prepared by the thin film hydration method [40]. Briefly, Soluplus® (400 mg),
Solutol® HS15 (400 mg) and TQ (25 mg) were dissolved in 10 mL CH3OH/CH2Cl2 mixture (1:4 v/v).
Then, solvents were left to evaporate at 30–35 ◦C under vacuum for 20 min, until the formation of a
film. Then, the film was hydrated with 5 mL of distilled water under sonication for 5 min to form
a micellar dispersion. Blank mixed micelles SSM were prepared according to the aforementioned
procedures without adding TQ.
3.3. Physical Characterization of TQ-SSM
The physical characterization was defined using Dynamic Light Scattering (DLS) by using Zsizer
Nanoseries ZS90 (Malvern Molecules Instrument, Worcestershire, UK) at 25 ◦C for the determination
of average diameter and the size distribution (polydispersity index, PDI) and Electrophoretic Light
Scattering technique (ELS) employing the same instrument to assess the zeta potential. The results
were expressed as the average of three measurements.
3.4. Drug Loading and Encapsulation Efficiency
The drug loading (DL%) and encapsulation efficiency (EE%) were determined by membrane
filtration method [49]. TQ-SSM were filtered with a 0.20 µm filter membrane. The non-encapsulated
TQ was retained on the membrane, while 20 µL of the filtrate was disrupted with 980 µL of MeOH.
The amount of TQ encapsulated and loaded into polymeric micelles was quantified by HPLC:
the mobile phase consisted of (A) formic acid/water pH 3.2 and (B) acetonitrile. The flow rate was
set at 0.8 mL/min. The gradient profile was: 0.10–25 min 10–90% B, 25–27 min 9% B, 27–30 min
10% B. For the calibration curve, different concentrations ranging from 0.002 µg/µL to 0.99 µg/µL
were used. The linear correlation coefficient was >0.999. The DL% and EE% were calculated by
equations (1) and (2), respectively:
DL% =
Weight of TQ in nanomicelles
Weight of fed + Weight of the excipients
× 100 (1)
EE% =
Weight of TQ in nanomicelles
Weight of TQ fed
× 100 (2)
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3.5. Theoretical Critical Micellar Concentration (CMCtheor)










XSoluplus and XSolutol are the molar fractions of Soluplus® and Solutol®, and CMCSoluplus and
CMCSolutol are the CMC values of Soluplus® and Solutol®, respectively. XSoluplus and XSolutol were
calculated by the ratio between the moles of the constituent and the total moles of the constituents of
the mixture.
3.6. Cloud Point
For the determination of the cloud point, the glass tubes containing 4 mL of TQ-SSM or SSM were
immersed in a water bath at room temperature. Then, the temperature increased and the change of the
sample from clear to turbid was observed. After that, the micellar formulations were cooled down and
the measurements were performed in triplicate [62,63].
3.7. Lyophilization
TQ-SSM were frozen with liquid nitrogen and then placed into the freeze-drier Leybold Heraeus
Lyovac GT2 equipped with a display for vacuum and temperature (Leybold GmbH, Cologne, Germany).
The lyophilization was performed at a reduced pressure of 1 atmosphere for 24 h. The lyophilized
samples (TQ-SSML) were placed in a silica gel desiccator at room temperature until the analysis.
The average particle hydrodynamic diameter, the homogeneity, the surface charge and the EE% were
determined after reconstitution of the powder with the original volume of distilled water. To ensure
the complete dispersion of the powder the samples were vortexed for a few minutes.
3.8. Stability Studies
3.8.1. Storage Stability Studies
The physical and chemical stability of TQ-SSM was investigate. The micellar dispersion is kept
straight after their preparation without a further step and it was transferred into glass bottles sealed
with plastic caps and stored at 4 ◦C over a period of 40 days while freeze-dried product (TQ-SSML)
was stored at room temperature for 30 days.
The average size, PDI, zeta potential, EE%, DL% and any the clarity condition of the micelles
systems were observed every week to evaluate the storage stability. Also, in the case of TQ-SSML the
appearance of the powder and the redispersibility time were evaluated. The physical and chemical
characterization was determined after reconstitution of the powder TQ-SSML with the distilled water.
3.8.2. Stability in Blood Conditions
The average diameter and size distribution of TQ-SSM and SSM were evaluated after 1 h of
incubation in PBS (pH 7.4) in the absence or in the presence of human serum albumin at a physiological
concentration (Human Serum Albumin (HSA), 45 mg/mL). The samples were diluted into the media
to obtain a HSA concentration of 0.5 mg/mL, then were incubated for 1 h at 37 ◦C under shaking
(250 rpm). At scheduled time points (30 min, 1 h), aliquots of the samples were collected for DLS
analyses [64,65]. The assays were performed in triplicate.
3.9. In Vitro Release Study
The in vitro release behavior of the TQ-SSM was studied using the dialysis bag method [40]. Two
mL of TQ-SSM were added to a dialysis membrane (regenerated cellulose, Spectrum Laboratories
Inc., Breda, The Netherlands, MWCO 3,5 kD) and immersed in 200 mL of the release media at 37 ◦C
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under magnetic stirring. PBS with 0.5% Tween® 80 was selected as release media. The released TQ
was under the sink conditions. Maintaining a sink condition means keeping the drug concentration
in a release medium low enough not to affect the concentration gradient for drug release. For this
aim, at predetermined time intervals, 1 mL of release medium was withdrawn for HPLC analyses
and replaced with the same volume of fresh release medium. The release was monitored during 24 h.
All experiments were performed in triplicate.
3.10. Cell Line and Treatment Conditions
SH-SY5Y human neuroblastoma cells were purchased from American Type Culture Collection
(ATCC®, Manassas, VA, USA). Cells were grown in a 1:1 mixture of DMEM and Ham’s F12
supplemented with 2 mM L-glutamine, 100 µg/mL streptomycin, 100 U/mL penicillin and 10%
FBS (complete medium), at 37 ◦C in a humidified atmosphere containing 5% CO2. At 90% confluence
cells were appropriately propagated after trypsinization (trypsin 0.025%-EDTA 0.5 mM).
Wound-healing assays were performed on SH-SY5Y cells in serum-free medium (starvation
medium) for 24 h in the presence of unformulated TQ at the final concentrations of 1.5 µM to 15 µM.
The TQ-loaded polymeric micelles (TQ-SSM) were examined at appropriate dilutions so that the
concentrations of TQ loaded in SSM were the same as those of unformulated TQ. Both cells untreated
and treated with empty SSM were used as controls.
3.11. Cell Viability Assay
The viability of SH-SY5Y cells was assessed with the MTT assay, adapted to the cells used in this
work. Cells were seeded in a 96-well plate (with a density of 5 × 103/well) in the complete medium and
allowed to grow overnight. Thereafter, a 24-h cell treatment in starvation medium with TQ at variable
concentrations and TQ-SSM at appropriate dilutions was performed. Moreover, the effect of empty
SSM on cell viability was investigated and untreated cells were used as a control. Once removing the
medium, 100 µL/well of an MTT solution (0.5 mg/mL) was applied. After 1 h of incubation within the
dark at 37 ◦C and washing in PBS, cells were lysed using 100 µL/well of a lysis buffer consisting of 20%
(w/v) sodium dodecyl sulfate (SDS) in 50% (v/v) N,N-dimethylformamide. Finally, absorption values
were recorded at 595 nm using a microplate reader (iMARK, Bio-Rad, Philadelphia, PA, USA). All data
were reported as percentage ratios with respect to untreated control cells.
3.12. Wound-Healing Assay
The wound-healing assay was used to evaluated SH-SY5Y cell migration into the wounded
area [39,66,67]. Cells were seeded in 6-well plate at the density of 5 x105 cells/well in complete medium
and were let to grow until a confluence monolayer was reached. Then, a longitudinal scratch was
generated in the cell monolayer using a sterile 200 µL pipette tip. Cell debris was removed by washing
in PBS and cells were treated with TQ at the different concentrations or TQ-SSM opportunely diluted in
the culture medium. The empty SSM was checked for its effect on cell migration. Untreated cells were
used as control. Cell-free area was observed with phase contrast microscope and images were taken at
a time interval of 0, 5, 7 and 24 h after the scratch using a Nikon TS-100 microscope equipped with a
digital acquisition system (Nikon Digital Sight DS Fi-1, Nikon, Minato-ku, Tokyo, Japan). Data were
analyzed by quantitatively measuring the distance traveled horizontally by SH-SY5Y cells between the
edges marked along each wound. The wound width data at each time were expressed in percentage
terms with respect to the width of the wound at the initial time.
3.13. Statistical Analysis and Graphics Preparation
The experiments were repeated three times and results were expressed as a mean ± standard
deviation. The statistical analysis of cell assay was performed with Tukey’s test.
Furthermore, the graphs were drawn using LibreOffice Calc. Panels were assembled with LibreOffice
Impress and adapted with Gimp 2.8.
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4. Conclusions
In the current study, Soluplus® and Solutol® HS15 mixed micelles was used as an optimal
system to enhance the ability of TQ to inhibit cancer cell migration. The solubility of TQ increased
of about 10-fold and the micelles have good physical parameters and high encapsulation efficiency.
Their stability as colloidal dispersion was demonstrated for a 40 days’ period. The lyophilization
process was considered to produce a dosage form with increased stability. The process does not alter
physical and chemical characteristics of the micelles. Due to the encapsulation into SSM, TQ efficiency
increased and the controlled drug release was improved. SSM are particularly useful for targeting
water-insoluble drug administration. Moreover, results from the in vitro wound-healing model
showed that SSM were able to improve the ability of TQ to inhibit human SH-SY5 Y neuroblastoma
cell migration. As for all pharmacological investigations, a pre-clinical in vitro study is foreseen before
proceeding to an in vivo experimentation. Therefore, given the achieved results the efficacy of TQ
loaded into these nanoformulations will be further investigated through in vivo animal models.
Overall, the ability to increase solubility and improve the stability and permeability of poor
lipophilic drugs makes polymeric micelles, also related to the constituents of carrier, a promising
delivery system for parenteral administration.
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